Evidence map›Paper›PMID 31886839›Full record

ArticleJAMA neurology2020

Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).

Christina N Fournier, Richard Bedlack, Colin Quinn, James Russell, Diane Beckwith, Kathleen H Kaminski, William Tyor, Vicki Hertzberg, Virginia James, Meraida Polak and 1 more

Registry-linked trialAbstract readValidation Study
In one paragraph

Article in JAMA neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491732 (Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491732 recruitingnot on this mapstarted 2025, after this paper: background citation

Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker

TypeobservationalSponsorBeth Israel Deaconess Medical CenterRan2025 to 2027Enrolled80ConditionsAmyotrophic Lateral SclerosisArmsElectrical Impedance Myography
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Estimating the minimum important difference in the ALSFRS-R-instrument in people living with MND.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025
    Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Multimodal Speech Biomarkers for Remote Monitoring of ALS Disease Progression.medRxiv : the preprint server for health sciences · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christina N FournierAtlanta VA Medical Center, Atlanta, Georgia.
Richard BedlackDuke University, Durham, North Carolina.
Colin QuinnUniversity of Pennsylvania, Philadelphia.
James RussellLahey Clinic, Burlington, Massachusetts.
Diane BeckwithEmory University, Atlanta, Georgia.
Kathleen H KaminskiAtlanta VA Medical Center, Atlanta, Georgia.
William TyorAtlanta VA Medical Center, Atlanta, Georgia.
Vicki HertzbergEmory University, Atlanta, Georgia.
Virginia JamesEmory University, Atlanta, Georgia.
Meraida PolakEmory University, Atlanta, Georgia.
Jonathan D GlassEmory University, Atlanta, Georgia.

Funding

Novel Prediction Tools for Amyotrophic Lateral SclerosisIK2CX001595 · VA · VETERANS HEALTH ADMINISTRATION · PI FOURNIER, CHRISTINA NICOLE · 2017 to 2021
–
6 · The paper itself

Abstract

Importance: A new outcome measure for overall disability level with improved responsiveness is needed for amyotrophic lateral sclerosis (ALS) clinical trials. Objective: To describe the creation and development of a new self-reported ALS disability scale with improved item targeting and psychometric properties that used a mathematically rigorous Rasch methodology. Design, Setting, and Participants: A preliminary ALS disability questionnaire with 119 questions was created based on literature review, clinical judgement of an expert panel, and patient input. Patients with ALS were recruited from January 2017 to June 2019 from the Emory University and Atlanta VA Medical Center ALS clinics, both in Atlanta, Georgia, during regularly scheduled clinic appointments to complete the draft questionnaire and standard ALS outcome measures. All consecutive patients seen at the Emory University and Atlanta VA Medical Center ALS clinics during the recruitment period with a diagnosis of ALS who were able to provide informed consent were invited to participate in the study. Rasch analyses were performed, and items were systematically removed based on missing data, model fit, disordered thresholds, item bias, and clinical judgment. A total of 509 patients with ALS were seen at the 2 sites during the recruitment period, and 264 patients provided informed consent. Interventions: Participants completed the draft Rasch questionnaire and the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Main Outcomes and Measures: Rasch analyses and standard scale metrics were performed to create the new scale, and Rasch analyses were performed on the ALSFRS-R for comparison. Results: Overall, 243 participants with ALS completed the draft questionnaire, and 230 participants were included for Rasch analyses. The mean (SD) age for study participants was 61.9 (11.1) years, 146 (60.1%) were men, and site of onset was 23.0% bulbar (n = 56), 36.2% upper extremity (n = 88), and 39.5% lower extremity (n = 96). A 28-question Rasch-Built Overall ALS Disability Scale (ROADS) was constructed with each item scored 0, 1, or 2. The ROADS fulfilled Rasch model requirements, demonstrated improved item targeting compared with the ALSFRS-R, and had test-retest reliability of 0.97. Individual question fit statistics demonstrated infit values from 0.68 to 1.37 and outfit values from 0.66 to 1.43. The difference between the empirical variance explained by the measures and the modeled variance was 0.1%. The ALSFRS-R violated Rasch model expectations and demonstrated disordered thresholds for 9 of 12 questions; 13 of 48 answer choices on the ALSFRS-R were never the most probable answer choice for any overall disability level. Conclusions and Relevance: In this study, the 28-question, self-reported ROADS, which is linearly weighted, had improved item targeting compared with the ALSFRS-R, had high test-retest reliability, and was validated. ROADS may serve as a valuable and easily accessible outcome measure for use in ALS trials and in the clinic with improved responsiveness compared with the ALSFRS-R.

Indexed as

AgedAmyotrophic Lateral SclerosisDisability EvaluationFemaleHumansMaleMiddle AgedPersons with DisabilitiesReproducibility of ResultsSeverity of Illness IndexSurveys and Questionnaires

Identifiers

PMID31886839
PMCPMC6990811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.